Systematic literature review of the global burden of illness of mantle cell lymphoma
Neerav Monga, Jamie Garside, Joan Quigley, Moira Hudson, Peter O’Donovan, John O’Rourke, Christoph Tapprich, Lori Parisi, Matthew S. Davids, Constantine S. Tam
Abstract
Background: Mantle cell lymphoma (MCL), a rare and aggressive disease, accounts for approximately 5% of all B-cell non-Hodgkin’s lymphomas. Evidence on the burden of this disease, for patients and healthcare providers, is scarce.Methods: Four systematic literature reviews were developed to identify epidemiological, real-world clinical, economic and humanistic burden data on patients with MCL. Electronic databases searched included MEDLINE and Embase, NHS EED and Econlit.Results: Eight epidemiological studies, 19 clinical burden, 2 economic impact and 0 quality of life studies were identified. The range of standardized MCL incidence rates was 0.1–1.27/100,000. Overall survival rates of patients at 3 years differed by age at diagnosis (≤65 years: 76–81%, >65 years: 46–64%) and disease stage (stage I: 73–80%, stage IV: 48–53%). Outcomes were poorer in previously treated patients, and those with later stage or blastoid disease, and improved with more recent diagnosis/treatment. Hospitalization is a major contributor to healthcare cost and differs by therapy toxicity.Conclusions: We identified significant data gaps for many G20 countries for epidemiology, real-world clinical, economic and humanistic burden. These literature reviews demonstrate the ongoing unmet need for MCL patients globally. Future research to further understand the real-world impact of MCL is needed along with new therapeutic options to improve patient outcomes.